Globus Medical (GMED) Reports Q4 Earnings: What Key Metrics Have to Say

Core Insights - Globus Medical reported revenue of $657.29 million for the quarter ended December 2024, reflecting a year-over-year increase of 6.6% and surpassing the Zacks Consensus Estimate by 2.02% [1] - The company's EPS for the quarter was $0.84, which is an increase from $0.60 in the same quarter last year, resulting in an EPS surprise of 10.53% over the consensus estimate of $0.76 [1] Revenue Breakdown - International revenues reached $135.40 million, exceeding the average analyst estimate of $133.48 million, marking a 7.7% increase year-over-year [4] - U.S. revenues totaled $521.89 million, surpassing the average estimate of $506.62 million, with a year-over-year growth of 6.3% [4] Product Category Performance - Net sales from Enabling Technologies were reported at $46.95 million, significantly higher than the estimated $38.17 million, representing a substantial year-over-year increase of 43.5% [4] - Net sales from Musculoskeletal Solutions amounted to $610.34 million, exceeding the average estimate of $597.20 million, with a year-over-year growth of 4.5% [4] Stock Performance - Over the past month, shares of Globus Medical have declined by 9.9%, contrasting with a 2.6% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]